The firm recently kicked off a study to determine whether a set of RNA-expression biomarkers can provide a high negative predictive value to rule out sepsis.
The firm said a test it has developed on the back of a large clinical trial detected cardioembolic stroke with 90 percent sensitivity and 70 percent specificity.
The firm had to delay an FDA EUA submission for a COVID-19 assay and extended the timeline for the anticipated launch of its COVID-19-flu molecular diagnostic test.
The firm expects that next year it will launch the final version of a battery-powered instrument that can perform high-level multiplexing and provide test results in 30 minutes.
During its annual strategic planning, the firm identified its expanding base of MDx instruments as an essential driver of increasing revenues.
Study investigators found that patients with ctDNA-positive results after surgery were at higher risk of bladder cancer recurrence than those who were ctDNA-negative.
The company has invested revenues from its pandemic testing business to buy assets that are growing faster than its base business.
MindX has inked a deal that enables Q2 Solutions to use whole-transcriptome analysis for psychiatric blood tests as part of an early-access program for physicians.
The firm said that recent validation studies have shown that a positive result with its PanCan-d microarray test could accelerate diagnosis for high-risk individuals.
On the back of a recently announced $3 million in funding, the firm has begun marketing its Urodiag kit to urologists throughout Europe.